Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System
Low Prices Seen Part Of Wider Problem
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.
You may also be interested in...
Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.
A new five-year strategic plan to counter antimicrobial resistance includes concrete new goals to reduce rates of resistance to specific drugs and support the development of new products.
Three quarters of the way through its financial year, Sawai has half as much cash on its balance sheet as it did at the same stage in 2021/22, as the Japanese firm continues to be dogged by lower government-mandated prices and higher costs at home.